Published in Volume
100, Issue 11 (December 1, 1997)
J Clin Invest. 1997;100(11):2824–2832.
doi:10.1172/JCI119830.
Copyright ©
1997, The American Society for
Clinical Investigation.
Research Article
Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2.
T Nakaoka, K Gonda, T Ogita, Y Otawara-Hamamoto, F Okabe, Y Kira, K Harii, K Miyazono, Y Takuwa and T Fujita
Fourth Department of Internal Medicine, School of Medicine, University of Tokyo, Tokyo 112, Japan.
Published December 1, 1997
Vascular proliferative disorders are characterized by the proliferation of vascular smooth muscle cells (SMCs) and excessive extracellular matrix synthesis. We found that bone morphogenetic protein-2 (BMP-2) inhibited serum-stimulated increases in DNA synthesis and cell number of cultured rat arterial SMCs in a fashion quite different from that in the case of transforming growth factor-beta1 (TGF-beta1). In addition, TGF-beta1 stimulated collagen synthesis in SMCs, whereas BMP-2 did not. In an in vivo rat carotid artery balloon injury model, the adenovirus-mediated transfer of the BMP-2 gene inhibited injury-induced intimal hyperplasia. These results indicate that BMP-2 has the ability to inhibit SMC proliferation without stimulating extracellular matrix synthesis, and suggest the possibility of therapeutic application of BMP-2 for the prevention of vascular proliferative disorders.